Denali Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditio...
Latest News
3 days ago · seekingalpha.com
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptDenali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
3 days ago · seekingalpha.com
Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)I initiate Denali Therapeutics at Buy, as the Avlayah launch has validated the TransportVehicle platform and turned DNLI into a commercial-stage story. Q3 Avlayah sales of $17.8M crushed the $10-12M guide, and Q4 guidance of $30-32M implies 65%+ sequential growth. DNL126 in Sanfilippo A is heading toward a 2027 accelerated-approval BLA and reuses the Avlayah commercial playbook almost one-for-one.
3 days ago · marketbeat.com
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones NearDenali Therapeutics NASDAQ: DNLI is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, while preparing data updates across a pipeline that includes treatments for Sanfilippo syndrome, Pompe disease and Alzheimer's disease.
11 days ago · zacks.com
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
13 days ago · seekingalpha.com
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call TranscriptDenali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
13 days ago · marketbeat.com
Denali Therapeutics Q3 Earnings Call HighlightsDenali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of clinical-trial participants to commercial therapy supported a faster-than-expected launch.
13 days ago · zacks.com
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue EstimatesDenali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.
18 days ago · globenewswire.com
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology ProductSOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation. AVLAYAH is the first biologic approved by the U.S. Food and Drug Administration (FDA) that is specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme replacement therapy that received FDA accelerated approval in March 2026 for the treatment of neurologic manifestations of a rare neurodegenerative disease called Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory study.
25 days ago · globenewswire.com
Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026.
2 months ago · seekingalpha.com
Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptDenali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove DNLI